Ro, the leading direct-to-patient healthcare company, today announced that it is working with Eli Lilly to launch the recently FDA-approved Zepbound® (tirzepatide) KwikPen® nationwide on its platform. The prefilled, multi-dose pen offers a convenient way for patients to take the most effective GLP-1 medication available. Patients can visit Ro.co to access the KwikPen along with ongoing high-quality clinical care, including 24/7 messaging, 1-1 coaching, educational content, weight tracking and dose logging, side-effect monitoring, and more.